Details:
Under the agreement, Kyverna gains access to LentiVector® platform, the first commercially approved lentiviral-based gene delivery system, to use with any Kyverna product, including its anti-CD19 CAR T-cell therapies, KYV-101 and KYV-201 which specifically target CD19.
Lead Product(s): KYV-101
Therapeutic Area: Immunology Product Name: KYV-101
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Kyverna Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 20, 2023
Details:
The funding will allow Zura Bio to initiate a Phase 2 clinical trial for ZB-106 (tibulizumab), a potential first-in-class anti-IL-17 and anti-BAFF dual antagonist, in systemic sclerosis (SSc), followed by a Phase 2 clinical trial in hidradenitis suppurativa (HS).
Lead Product(s): Tibulizumab
Therapeutic Area: Immunology Product Name: ZB-106
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Deep Track Capital
Deal Size: $80.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement June 06, 2023
Details:
The net proceedings will be used to to initiate a Phase 2 study for ZB-106 (tibulizumab), a potential first-in-class, anti-IL-17 and anti-BAFF dual antagonist, in Systemic Sclerosis.
Lead Product(s): Tibulizumab
Therapeutic Area: Immunology Product Name: ZB-106
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Deep Track Capital
Deal Size: $80.0 million Upfront Cash: $80.0 million
Deal Type: Private Placement April 27, 2023
Details:
The acquisition provides Gilead with MiroBio’s proprietary discovery platform and entire portfolio of immune inhibitory receptor agonists. MiroBio’s lead MB272, is a selective agonist of immune inhibitory receptor B and T-Lymphocyte Attenuator.
Lead Product(s): MB272
Therapeutic Area: Immunology Product Name: MB272
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Gilead Sciences
Deal Size: $405.0 million Upfront Cash: $405.0 million
Deal Type: Acquisition September 20, 2022
Details:
The acquisition will provide Gilead, MiroBio’s proprietary discovery platform and entire portfolio of immune inhibitory receptor agonists. MiroBio’s lead investigational antibody, MB272, is a selective agonist of immune inhibitory receptor B- and T-Lymphocyte Attenuator.
Lead Product(s): MB272
Therapeutic Area: Immunology Product Name: MB272
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Gilead Sciences
Deal Size: $405.0 million Upfront Cash: $405.0 million
Deal Type: Acquisition August 04, 2022
Details:
Proceeds to support advancement of pipeline of small molecule NLRP3 inflammasome inhibitors, including continued progression of NT-0167 through clinical development.
Lead Product(s): NT-0167
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Novo Holdings
Deal Size: $55.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing June 03, 2020